Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5845250 | 0.99 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CCR2OPRM1 | |
| SCHEMBL5162722 | 0.85 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3OPRM1OPRL1 | |
| SCHEMBL5846576 | 0.84 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CCR2OPRM1 | |
| Hydrochloric Acid SCHEMBL5845093 | 0.84 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL5845587 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CCR2OPRM1 | |
| SCHEMBL6937438 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRL1 | |
| SCHEMBL6936266 | 0.83 | MEN1 (0.32) | NPC1RAB9A | |
| SCHEMBL6939785 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3OPRM1OPRL1 | |
| SCHEMBL6936977 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3OPRM1OPRL1 | |
| SCHEMBL6934438 | 0.77 | OPRK1 (0.40) | SLC6A2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1253917-B1 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-02-16 | — | — | EP | claimed |
| EP-1043307-B1 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | GRUENENTHAL GMBH (DE) | 2003-06-04 | — | — | EP | claimed |
| US-20030008859-A1 | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-01-09 | — | — | US | claimed |
| EP-1253917-A2 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2002-11-06 | — | — | EP | claimed |
| US-6410790-B1 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2002-06-25 | — | — | US | claimed |
| WO-2001047506-A2 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2001-07-05 | — | — | WO | claimed |
| EP-1043307-A2 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | Grünenthal GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| US-7012099-B2 | Using substituted 4-amino-1- phenylbutan-2-ol compounds in form of their racemates, enantiomers, diastereoisomers or corresponding bases or corresponding salts of acids as regulators for the nociceptin/orphanin FQ ligands in drugs | GRUENENTHAL GMBH (DE) | 2006-03-14 | — | — | US | disclosed |
| EP-1253917-B1 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-02-16 | — | — | EP | disclosed |
| EP-1043307-B1 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | GRUENENTHAL GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008859-A1 | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1253917-A2 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6410790-B1 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2002-06-25 | — | — | US | disclosed |
| WO-2001047506-A2 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2001-07-05 | — | — | WO | disclosed |
| EP-1043307-A2 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | Grünenthal GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008859-A1 | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | OPRL1, OPRM1, OPRK1 | SLC6A2 1098/4885SLC6A4 1019/4885SLC6A3 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.